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Background.The value of a histologic classification scheme to classify patients with anti-neutrophil cytoplasmic antibody-associated
glomerulonephritis (ANCA-GN) into focal, mixed, crescentic, and sclerotic types for predicting risk of end-stage renal disease
(ESRD) is well documented. However, the prognostic value of histological classification specifically in elderly patients (≥70
years) with ANCA-GN has not previously been investigated. Methods. Patients with biopsy-verified pauci-immune necrotizing
glomerulonephritis were identified from the Norwegian Kidney Biopsy Registry between 1991 and 2012 and those ≥70 years of age
at the time of diagnosis andhaving positive anti-neutrophil cytoplasmic antibody serologywere included in this study.The incidence
rate of ESRD and/or deathwas determined by linking the study cohort to theNorwegian Renal Registry and the Population Registry
of Norway.The ESRD-free survival and patient survival were compared between the 4 histological types. Results. Of the 81 patients
included, 20 progressed to ESRD and 34 died. The 1-year and 5-year ESRD-free survival varied between histological groups (𝑝 =
0.003) as follows: focal, 97% and 97%, respectively; mixed, 70% and 57%; crescentic, 76% and 63%; and sclerotic, 49% and 49%.
Patient survival did not differ significantly between groups (𝑝 = 0.30).Conclusion. Histological classification in elderly patients with
ANCA-GN is useful for predicting ESRD but not survival.
1. Introduction
Anti-neutrophil cytoplasmic antibody (ANCA) associated
vasculitis (AAV), which affects multiple organs, has histor-
ically been associated with a high risk of long-term mor-
bidity and mortality. The introduction of cyclophosphamide
treatment, more than 5 decades ago, has greatly improved
the prognosis of these patients [1]. However, even with
modern treatment, the risk of AAV-associated morbidity and
mortality remains high [2–4]. Although AAV can occur at
any age, the risk of a fatal course of AAV is particularly
high among elderly patients [5, 6], with the risk of death at
1 year being close to 50% among patients aged >80 years
[7]. Kidney involvement, in the form of focal necrotizing
glomerulonephritis (ANCA-GN), is frequent in patients with
AAV and is associatedwith a poorer clinical outcome, includ-
ing a substantial risk for end-stage renal disease (ESRD)
necessitating chronic renal replacement therapy, in the form
of dialysis or kidney transplantation [4]. Diagnostic kidney
biopsy plays an important role in establishing and confirming
the diagnosis of ANCA-GN [8, 9], as well as conveying
important prognostic information [10–18]. The most fre-
quently used and validated model to assess the prognostic
information from kidney biopsies for ANCA-GNdiagnosis is
a histological classification scheme that classifies patients into
4 types: focal (≥50% normal glomeruli), crescentic (≥50%
cellular crescents), mixed (<50% normal, <50% crescentic,
and <50% globally sclerotic glomeruli), and sclerotic (≥50%
globally sclerotic glomeruli) [19–34].
For several reasons, age might impact the validity and
clinical value of histological classification in patients with
ANCA-GN. Sclerotic glomeruli are often present as the result
of aging, and this can confuse histological classification. Fur-
thermore, while ESRD is the dominant outcome in younger
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patients, disease and/or treatment associated mortality is
more frequent among elderly patients [5, 7] and might act
as a competing end-point in survival analyses. In previous
studies, histological classification has not been found to be
useful for predicting survival among patients with ANCA-
GN [20]. Additionally, the risk associated with performing a
kidney biopsy increases in elderly patients due to age itself,
as well as comorbid conditions and the use of concomitant
medications [35]. Histological confirmation is preferred but
is not strictly necessary for diagnosingANCA-GN.Therefore,
should renal biopsy be performed in very old patients is an
important clinical question [36]. Evaluation of the prognostic
value of the histological classification of biopsy in elderly
patients with ANCA-GN is an important factor to consider
when addressing this clinical question.
Data on the prognostic value of histological classification
specifically in elderly patients with ANCA-GN are missing.
Here, using information from the Norwegian Kidney Biopsy
Registry (NKBR) and the Norwegian Renal Registry, we have
analyzed the prognostic value of the histological classification
in ≥70-year-old patients with ANCA-GN at the time of
diagnosis. Data stratified by age of 70–74.9 versus ≥75 years
were also analyzed using both ESRD and death as end-points.
2. Materials and Methods
The study was approved by the Regional Committee for
Medical and Health Research Ethics.
2.1. Identification of Study Cohort and Baseline Data. The
study groupwas selected from the research cohort used in our
previously published article “Prognostic Value of Histologic
Classification ofANCA-AssociatedGlomerulonephritis” [20]
and included patients with a biopsy-confirmed diagnosis of
ANCA-GN who were ≥70 years old at the time of diagnosis.
Our procedures for identifying our study cohort, the baseline
data of our cohort, the histological classification of patients,
definition of the period of observation, and identification of
the end-points for analysis (ESRD and death) are described
in detail in our previous paper, with relevant information for
this study summarized as follows.
All patients were ≥70 years old at the time of
diagnosis. Diagnosis was based on examination of biopsy
tissue containing at least 10 glomeruli, with histological
confirmation of ANCA-GN. All patients and their relevant
data were identified from the NKBR between 1991 and 2012.
The criteria for ANCA-GNwere a pauci-immune necrotizing
glomerulonephritis together with a positive ANCA titer. The
following baseline data were obtained from the NKBR for
analysis: sex, age, serum albumin, systolic blood pressure and
diastolic blood pressure, and proteinuria. ANCA serotype
was reported as analyzed by the clinician’s laboratory at time
of diagnosis. In the first part of the study period, ANCA was
determined by the indirect immunofluorescentmethod; after
approximately year 2000, the enzyme-linked immunosorbent
assay method has been used. Estimated GFR (eGFR) was
calculated from serum creatinine using the modified
Modification of Diet in Renal Disease formula. Before
year 2000, serum creatinine level was not standardized to
isotope-dilution mass spectrometry and therefore was
reduced by 5%. One of the authors (Leif Bostad), an
experienced renal pathologist, classified all cases according
to the histological classification schema of ANCA-GN.
2.2. Definition of Observation Period and Study End-Points.
The observation period was from the time of biopsy to a first
event of ESRD, death, or the end of the period of observation
on 31 December 2012. For analysis, the observation period
was stratified into the induction (≤1 year after biopsy) and
the remission (>1 year after biopsy) phases.The primary end-
point of this study was ESRD, defined as initiation of chronic
renal replacement therapy in the form of dialysis or renal
transplantation. ESRD cases were identified by linking the
study cohort to the Norwegian Renal Registry.The secondary
end-point of analysis was death, identified by linking the
study cohort to the Population Registry of Norway. Both
datasets were used to identify patients who developed ESRD
or died, whichever came first, over the follow-up period of the
study.
2.3. Statistical Analysis. Cases were classified into the focal,
mixed, crescentic, and sclerotic histological types and a
between-group comparison of baseline data was performed.
Baseline data were subsequently compared between patients
who survived and those who progressed to ESRD or died
during the induction phase.The 1-year and 5-year cumulative
ESRD-free survival was evaluated using Kaplan-Meier statis-
tics, both for the entire study cohort and after stratification
based on the histological classification. These analyses were
repeated using the secondary end-points, namely, death and
ESRD/death. Baseline data and outcomes were reanalyzed
after stratification into two age groups, 70–74.9 years versus
≥75 years at time of diagnosis. Finally, we compared the out-
comes of our study cohort to outcomes previously reported
in the two largest studies on ANCA vasculitis in elderly
patients. For significance testing, the chi-squared test was
used for categorical variables, the Mann–Whitney 𝑈 test for
continuous variables, and the log-rank test for comparisons
of survival. All analyses were performed using SPSS (version
24).
3. Results
3.1. Cohort Characteristics and Outcomes. Our study cohort
included 81 patients (45 women (56%) with a mean age of 77
years (standard deviation (SD), 5 years)). 47 (58%) patients
were perinuclear- (P-) or myeloperoxidase- (MPO-) ANCA
positive. The mean eGFR was 27 ml/min/1.73m2 (SD, 23)
and 38% (SD, 28%) of glomeruli presented without crescents
or global sclerosis. Other relevant baseline characteristics are
presented in Table 1.
The median observation period was 2.2 years (25th–75th
percentiles, 0.2-5.6 years), with 279 patient years. During
the short-term follow-up period (≤1 year), 15 (19%) patients
required initiation of chronic renal replacement therapy and
17 (21%) patients without ESRD died.
49 (60%) patients survived >1 year after the diagnosis
of ANCA-GN without ESRD, with 5 (6%) of these patients
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Table 1: Baseline characteristics for the total cohort, stratified by histological classification.
Characteristic All, 𝑛 = 81 Focal, 𝑛 = 32 Crescentic, 𝑛 = 18 Mixed, 𝑛 = 22 Sclerotic, 𝑛 = 9 𝑝 value
Female (%) 45 (56) 14 (44) 10 (56) 14 (64) 7 (78) 0.24
Age, years (SD) 77 (5) 76 (5) 77 (5) 77 (5) 76 (4) 0.79
P-/MPO-ANCA (%) 47 (58) 18 (56) 11 (61) 11 (50) 7 (78) 0.55
eGFR, ml/min/1.73m2
(SD) 27 (23) 36 (24) 15 (9) 22 (19) 27 (36) 0.001
Serum albumin, gram/l
(SD) 30 (6) 32 (6) 28 (4) 31 (5) 30 (5) 0.06
Systolic blood pressure
(SD) 147 (23) 143 (21) 144 (27) 149 (23) 158 (24) 0.48
Diastolic blood pressure
(SD) 79 (12) 80 (14) 81 (13) 77 (9) 83 (6) 0.37
Proteinuria, gram/24 h
(SD) 1.4 (1.4) 1.1 (1.2) 1.2 (0.9) 1.7 (1.8) 1.4 (1.2) 0.39
Percentage of normal
glomeruli (SD) 38 (28) 68 (12) 14 (16) 24 (11) 4 (6) <0.001
SD, standard deviation.
(a) (b)
Figure 1: (a) Flowchart of patient outcomes at 0-1 year of observation. (b) Flowchart of patient outcomes at >1 year of observation.
later progressing to ESRD. At the end-point of the study
in 2012, 17 (21%) patients without ESRD had died. Causes
of death were cardiovascular disease, 21%, malignancies,
12%, vasculitis/treatment associated infection, 45%, and other
causes, 21%. 27 patients (33%) were alive without ESRD
(Figures 1(a) and 1(b)). At the study end-point, only 4 of the
20 patients with ESRD had survived.
Baseline data stratified by histological classification are
reported in Table 1. Baseline eGFR was different among
the 4 groups (𝑝 = 0.001), with a mean eGFR of 36
ml/min/1.73m2 for the focal group, 27 for the sclerotic
group, 22 for the mixed group, and 15 for the crescentic
group. Finally, the percentage of normal glomeruli was also
different among the 4 groups, with 68% normal glomeruli
in the focal group, 24% in the mixed group, 14% in the
crescentic group, and 4% in the sclerotic group (p <
0.001).
3.2. Comparison of Survivors and Nonsurvivors. Comparison
of baseline characteristics between the 49 patients who
survived 1 year after ANCA-GN diagnosis without ESRD
(survivors) and the 32 patients who progressed to ESRD
or died in the first year after diagnosis (nonsurvivors) is
reported in Table 2. Between-group differences were identi-
fied for the following baseline characteristics: percentage of P-
/MPO-ANCA, 67 versus 44% for survivors and nonsurvivors,
respectively; eGFR, 33 versus 18ml/min/1.73m2, respectively;
serum albumin, 32 versus 28 gram/l, respectively; proteinuria,
1.1 versus 1.8 gram/24 h, respectively; percentage of normal
glomeruli, 49 versus 21%, respectively; and percentage with
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Table 2: Baseline characteristics stratified for presence or absence of end-stage renal disease-free survival at 1 year.
Characteristic Alive without ESRD, 𝑛 = 49 ESRD/death < 1 year, 𝑛 = 32 𝑝 value
Female (%) 29 (59) 16 (50) 0.42
Age (SD) 76 (5) 77 (5) 0.82
P-/MPO-ANCA (%) 33 (67) 14 (44) 0.64
eGFR (SD) 33 (22) 18 (22) <0.001
Serum albumin (SD) 32 (6) 28 (5) <0.001
Systolic blood pressure (SD) 146 (22) 147 (25) 0.89
Diastolic blood pressure (SD) 78 (12) 81 (11) 0.55
Proteinuria (SD) 1.1 (1.1) 1.8 (1.6) 0.02
Percentage of normal glomeruli (SD) 49 (26) 21 (23) <0.001
Focal (%) 26 (53) 6 (19) 0.002
Mixed (%) 13 (27) 9 (28) 0.88
Crescentic (%) 7 (14) 11 (34) 0.03
Sclerotic (%) 3 (6) 6 (19) 0.08
SD, standard deviation; eGFR, estimated glomerular filtration rate.
focal (53 versus 19%, resp.) and crescentic (14 versus 34%,
resp.) histology.
3.3. Cumulative Risk of ESRD, Death, and ESRD/Death
Stratified for Histological Classification. Cumulative survival
at 1 and 5 years without ESRD among whole study cohort and
after stratification according to the histological classification
model is reported in Table 3(a) and Figure 2(a). The 1-year
ESRD-free survival and 5-year ESRD-free survival for the
whole study cohort were 80% and 73%, respectively. Survival
was different among the 4 histological groups (𝑝 = 0.003),
with 1-year survival and 5-year survival of 97% and 97%,
respectively, for the focal group, 70% and 57% for the mixed
group, 76% and 63% for the crescentic group, and 49% and
49% for the sclerotic group. The corresponding percentages
for death at 1 year and 5 years, including death occurring after
commencement of renal replacement therapy, were 73% and
50%, respectively, for the whole study group, with no differ-
ence among the 4 histological groups (𝑝 = 0.30; Table 3(b)):
81% and 62%, respectively, for the focal group; 73% and 39%
for the mixed group; 56% and 44% for the crescentic group;
and 78% and 56% for the sclerotic group. Cumulative 1-year
survival and 5-year survival without ESRD/death were 61%
and 42%, respectively, for the whole study group, with a
significant difference between the 4 histological groups (𝑝
= 0.02): 81% and 62%, respectively, for the focal group; 59%
and 35% for the mixed group; 39% and 21% for the crescentic
group; and 33% and 33% for the sclerotic group (Table 3(c)
and Figure 2(b)).
3.4. Comparison of Patients Aged 70–74.9 versus ≥75 Years.
Comparison of baseline data according to age stratification,
70–74.9 versus ≥75 years, is reported in Table 4. Between-
group differences were identified only for mean age, 73 and
80 years, respectively (𝑝 < 0.001). Cumulative survival (0 to 5
years after biopsy) without ESRD, death, and ESRD/death for
each age group is shown in Figures 3(a)–3(c). For the 70–74.9
Table 3
(a) End-stage renal disease-free survival at 1 year and 5 years for the total
cohort, stratified by histological classification
Characteristic N ESRD 1 year 5 years 𝑝 value
All 81 20 80 % 73 %
Focal 32 1 97 % 97 %
Mixed 22 10 70 % 57 %
Crescentic 18 5 76 % 63 % 𝑝 = 0.003
Sclerotic 9 4 49 % 49 %
(b) Patient survival at 1 year and 5 years for the total cohort, stratified by
histological classification
Characteristic N Death 1 year 5 years 𝑝 value
All 81 50 73 % 50 %
Focal 32 15 81 % 62 %
Mixed 22 16 73 % 39 %
Crescentic 18 14 56 % 44 % 𝑝 = 0.30
Sclerotic 9 5 78 % 56 %
(c) Patient and end-stage renal disease-free survival at 1 year and 5 years of
follow-up in total cohort, stratified according to histological classification
Characteristic N ESRD/death 1 year 5 years 𝑝 value
All 81 54 61 % 42 %
Focal 32 15 81 % 62 %
Mixed 22 71 59 % 35 %
Crescentic 18 16 39 % 21 % 𝑝 = 0.02
Sclerotic 9 6 33 % 33 %
versus ≥75 years group, respectively, the cumulative ESRD-
free 1-year survival was 84% and 77%, with 5-year survival of
74% and 73%. The cumulative patient survival was 74% and
27% at 1 year and 60% and 44% at 5 years, with cumulative 1-
year survival without ESRD/death of 65% and 57% and 5-year
survival of 54% and 34%.There was no effect of age group on
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Table 4: Baseline characteristics stratified by age, 70–74.9 years and ≥75 years, at time of inclusion.
Characteristic Age 70–74.9 years, 𝑛 = 34 Age ≥75 years, 𝑛 = 47 𝑝 value
Female (%) 18 (53) 27 (57) 0.68
Age, years (SD) 72 (1) 80 (4) <0.001
P-/MPO-ANCA (%) 20 (59) 27 (57) 0.90
eGFR, ml/min/1.73m2 (SD) 30 (25) 25 (22) 0.15
Serum albumin, gram/liter (SD) 31 (7) 30 (5) 0.46
Systolic blood pressure (SD) 145 (22) 148 (24) 0.52
Diastolic blood pressure (SD) 81 (11) 78 (13) 0.43
Proteinuria, gram/24 hours (SD) 1.5 (1.2) 1.3 (1.5) 0.06
Percentage of normal glomeruli (SD) 44 (26) 34 (29) 0.13
Focal histology (%) 17 (50) 15 (32) 0.10
Mixed histology (%) 8 (24) 14 (30) 0.53
Crescentic histology (%) 6 (18) 12 (26) 0.40
Sclerotic histology (%) 3 (9) 6 (13) 0.58
SD, standard deviation; eGFR, estimated glomerular filtration rate.
(a) (b)
Figure 2: (a) Kaplan-Meier plot showing end-stage renal disease-free survival according to histological classification. (b) Kaplan-Meier plot
showing patient and end-stage renal disease-free survival according to histological classification.
the survival without ESRD or death and ESRD/death across
the 4 histological groups.
3.5. Comparison of Outcomes Reported in International Stud-
ies. Bomback et al. reported the 1-year risk of ESRD, deaths,
and the combination of ESRD and death among 61 patients,
>80-year-old, with ANCA-GN [7]. ESRD and death risk
were reported stratified according to the use or nonuse of
immunosuppressive therapy in treated and untreated groups,
respectively. The 1-year ESRD-free survival was 64% for the
treated group and 27% for the untreated group. Specifically
for patients >80 years old in our study group, the 1-year
ESRD-free survival was 81%, compared to 54% for the treated
group and 36% for the untreated group in Bomback et al.’s
study. Our overall 1-year survival rate for patients >80 years
old was 74%. Finally, the 1-year rate of survival without ESRD
for this group of patients was 65% in our study, compared to
the 30% reported by Bomback et al.
Weiner et al. reported the 1-year and 2-year ESRD free-
survival and patient survival among 151 patients, >75 years
old, with ANCA vasculitis from Sweden, UK, and the Czech
Republic [5]. The ESRD-free survival was 75% at both the 1-
year and 2-year timepoint of follow-up. For patients>75 years
old in our study cohort, the ESRD-free survival rate was 77%
at 1 year and 73% at 2 years. With regard to overall patient
survival, Weiner et al. reported a rate of 72% at 1 year and
65% at 2 years, compared to 72% and 64%, respectively, in
our study cohort.
4. Discussion
To our knowledge, this is the first study reporting the prog-
nostic value of histological classification in elderly patients
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(a) (b)
(c)
Figure 3: (a) Kaplan-Meier plot showing end-stage renal disease-free survival in patients aged 70–74.9 years versus ≥75 years. (b) Kaplan-
Meier plot showing patient survival in patients aged 70–74.9 years versus ≥75 years. (c) Kaplan-Meier plot showing patient and end-stage
renal disease-free survival in patients aged 70–74.9 years versus ≥75 years.
(≥70 years) with ANCA-GN, and we demonstrate that the
classification predicts ESRD-free survival in this group.
This finding demonstrates that, despite the possibility for
sclerotic glomeruli due to aging which might affect patient
classification, histological examination still has prognostic
value for elderly patients. Moreover, the prognostic value
of histological classification is not lost due to deaths prior
to ESRD acting as a competing end-point. Finally, no fatal
complications following kidney biopsy were reported.
Among our study cohort, however, histological classifi-
cation was not predictive of overall survival of patients with
ANCA-GN, which is slightly surprising given the high mor-
tality rate among elderly patients having advanced kidney
function impairment or receiving renal replacement therapy.
As in other studies reporting outcomes in elderly patients
with ANCA vasculitis, death significantly outnumbers ESRD
as the end-point of analysis [5, 7]. Given this high disease
and treatment associated mortality rate, it would be reas-
suring for clinicians to have a tissue confirmed diagnosis of
ANCA-GN when treating this patient group. Thus, although
tissue confirmation is not strictly necessary to diagnose
ANCA-GN, our findings support the clinical value of kid-
ney biopsy, whenever feasible, including in elderly patients
[36].
Comparison of baseline characteristics stratified by his-
tological classification demonstrated that the percentage of
normal glomeruli and initial eGFR was significantly higher
among patients with focal histology, which was in agreement
with previous studies in all cohorts having reported the
histological classification of patients with ANCA-GN.
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We identified a number of factors that can influence the
probability of a patient being alive without ESRD at 1-year
after diagnosis, including eGFR, serum albumin, proteinuria,
percentage of normal glomeruli, focal histology, and crescen-
tic histology. These factors have been identified in previously
published research and, therefore, were not surprising [4].
Interestingly, although female sex tended to be associated
with a better outcome, this between-sex difference did not
reach statistical significance. It is, however, surprising that
P-/MPO-ANCA as compared to C-/PR3-ANCA positivity
was associated with a significantly better outcome. Several
previous studies including younger age groups have identified
P-/MPO-ANCA positive serology as a negative prognostic
marker for both progression to ESRD and patient survival
[37].
Our comparison of the effects of age, stratified into
70–74.9 and ≥75 years, demonstrated no significant dif-
ferences in baseline characteristics and outcomes. These
findings indicate that age ≥70 years could be a reasonable
cutoff for studies reporting outcomes in elderly patients with
ANCA-GN.
Comparisons of outcomes for our study cohort to those
from Bomback et al. and Weiner et al. demonstrated that
prognosis in elderly Norwegian patients with ANCA-GN
is at least comparable to that of other European countries
and USA [5, 7]. Obviously clinical outcomes will depend on
both the delay in diagnosis and the quality of therapy; the
extent to which these factors influence outcomes, however,
is uncertain.
The strengths of our study include the relatively large
study cohort, its population-based nature, and identification
of end-points during follow-up from high-quality national
registries. Some weaknesses must also be recognized. Pri-
marily, the treatment of individual patients is not known.
We do know that cyclophosphamide and steroids were
almost exclusively used for the treatment of ANCA-GN in
Norway up to 2012, with exchange of cyclophosphamide for
azathioprine being used formaintenance treatment after 2003
[3, 17, 20]. We do not believe that Norwegian nephrologists
have performed diagnostic kidney biopsies in patients with
ANCA-GN unless treatment with immunosuppression was
an option; however, we cannot completely rule out the
possibility that some patients were untreated. Bomback et
al. and Weiner et al. reported a less favorable outcome
in the relatively few patients (11 and 7 patients, resp.) not
treated with immunosuppressive drugs [5, 7]. Although these
findings obviously might be confounded by indication for
treatment, the natural course of untreated ANCA-GN also
supports the use of immunosuppression for treatment of
this disease, including in elderly patients. The fact that the
outcomes of patients in the present study cohort were at least
in line with previous findings strongly indicates that cases
included in our study group were generally treated according
to established international standards. Another weakness of
our study is the lack of information regarding extrarenal
vasculitis activity. Such data have not been registered in the
NKBR, which primarily has focused on kidney disease. In
Weiner et al.’s study, the BirminghamVasculitis Activity Score
did not associate with outcomes in the multivariate analysis,
indicating that the lack of such data in the present study
perhaps is not a major weakness [5].
In conclusion, we have demonstrated that histological
classification predicts risk of ESRD including in elderly
patients (≥70 years) with ANCA-GN, and this finding sup-
ports the diagnostic value of kidney biopsy for establishing
both the diagnosis and prognosis. Therefore, when feasible, a
biopsy should be performed to confirm diagnosis, including
in elderly patients.
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